Gilead Sciences Inc (GILD)
Gilead - U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Gilead - U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
PNC Releases Results of 2026 Dodd-Frank Company-Run Stress Test
Cantor Equity Partners I, Inc. Announces Postponement of Shareholder Meeting to 10:00 Am Eastern Time July 2, 2026
Jefferies Announces Second Quarter 2026 Financial Results
Grand Canyon Education, Inc. Announces Second Quarter 2026 Earnings Release Date and Conference Call Details
L3Harris Plans Arkansas Facility Expansion for PAC-3 Propulsion Production
Acuity Inc. Declares Quarterly Dividend
Ryman Hospitality Properties, Inc. Addresses Recent Media Reports Regarding Opry Entertainment Group
Jushi Holdings Inc. Announces Voting Results of Annual General and Special Shareholders’ Meeting